Last updated: August 3, 2025
Introduction
NDC 24208-0814 pertains to a pharmaceutical product listed within the U.S. National Drug Code (NDC) database. To inform strategic decisions, an in-depth analysis of its market landscape, competitive positioning, pricing trends, and future projections is essential. This report synthesizes available data, industry insights, and market dynamics to deliver a comprehensive outlook on this drug’s commercial potential.
Product Overview
The NDC 24208-0814 corresponds to Eliquis (apixaban), an oral anticoagulant marketed by Bristol-Myers Squibb and Pfizer. Approved for various indications, including atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE), Eliquis has become a leading anticoagulant in the U.S. market, surpassing rivals such as rivaroxaban and warfarin.
Market Landscape
Market Size and Growth Dynamics
The global anticoagulant market is projected to grow at a compound annual growth rate (CAGR) of approximately 7.1% through 2028, driven by the rising prevalence of cardiovascular diseases (CVD), diabetes, and thrombosis-related conditions [1]. In the U.S., the anticoagulant segment is estimated to reach USD 8.2 billion by 2025, with oral factor Xa inhibitors like apixaban constituting over 50% of sales [2].
Competitive Positioning
Eliquis commands a significant market share within this sector, competing primarily against Xarelto (rivaroxaban) and Pradaxa (dabigatran). The drug benefits from physician preference for its efficacy profile, safety, and reduced monitoring requirements compared to warfarin.
Regulatory and Reimbursement Factors
The drug enjoys broad formulary coverage, with favorable reimbursement terms contributing to robust utilization. However, pricing pressures from pharmacy benefit managers (PBMs) and increasing biosimilar/navigational alternatives influence market dynamics. Regulatory activities, including potential label expansions, could further affect demand.
Pricing Trends and Historical Data
Current Pricing Benchmarks
Based on latest data, the average wholesale price (AWP) for Eliquis ranges between $480 and $560 for a 30-tablet pack, depending on dosage strength and pharmacy discounts. The retail price after discounts and patient co-pays typically falls within a $350–$450 range [3].
Reimbursement and Patient Out-of-Pocket Expenses
Government programs such as Medicare Part D and private insurance influence out-of-pocket costs. Tier placement and formulary restrictions can modify net prices received by manufacturers and impact prescribing behaviors.
Market Penetration and Prescription Trends
The number of prescriptions for Eliquis has increased steadily, outpacing many competitors, partly due to robust clinical data and expanded indications. In 2022, quarterly prescription volumes surpassed 2 million in the U.S., signaling strong uptake [4].
Future Price Projections and Market Drivers
Factors Influencing Future Pricing
-
Patent Status and Generic Competition: Eliquis’s patent protection is expected to extend until at least 2028, with potential for license extensions or data exclusivity if approvals are granted for new indications. The entry of biosimilars or generics could significantly impact prices post-expiry.
-
Market Penetration and Indication Expansion: Regulatory approval for additional indications (e.g., prophylaxis in orthopedic surgeries) could stimulate demand, supporting sustained pricing.
-
Reimbursement Policies and Market Access: Evolving payer negotiations and emphasis on value-based care could challenge premium pricing. However, proven clinical benefits and real-world effectiveness may justify maintained or increased pricing in niche segments.
-
Cost of Development and Production: R&D expenses for new formulations or combination therapies may influence long-term pricing strategies, potentially elevating costs if innovation persists.
Projected Price Trajectory (2023–2030)
| Year |
Estimated Wholesale Price Range |
Key Market Drivers |
| 2023 |
$480 – $560 |
Existing demand, stable patent protection, established formulary position |
| 2024 – 2025 |
$470 – $550 |
Slight pricing pressure from competitive treatments, market saturation concerns |
| 2026 – 2028 |
$460 – $530 |
Patent expiry approaches, potential biosimilar entry |
| 2029+ |
$300 – $400 (post-patent expiry) |
Increased generic competition, biosimilar market penetration |
Note: These projections assume continued clinical reliance and moderate market pressures, with potential for deviations depending on regulatory and economic factors.
Strategic Insights
- Innovation and Differentiation: Ongoing development of improved formulations or adjunct therapies can sustain premium pricing.
- Market Expansion: Pursuing indications beyond cardiology, such as oncology-related thrombosis, could diversify revenue streams.
- Pricing Optimization: Building strong payer relationships and demonstrating cost-effectiveness could bolster reimbursement terms.
- Competitive Preparedness: Monitoring biosimilar developments and engaging in early negotiations will be critical as patent protections diminish.
Key Takeaways
- Eliquis (NDC 24208-0814) holds a dominant position in the anticoagulant market, with sales continuing to grow due to expanding indications and robust clinical data.
- Pricing remains relatively stable but faces potential downward pressure from impending patent expiry and biosimilar competition.
- Market growth is expected to sustain with a projected CAGR of over 7%, driven by rising CVD prevalence, aging populations, and new therapeutic opportunities.
- Strategic planning should focus on innovation, market expansion, and early response to biosimilar entry to preserve revenue margins.
- Post-patent era prices could decline substantially, emphasizing the need for cost management and value demonstration.
FAQs
1. When does the patent for Eliquis (apixaban) expire?
The primary patent protection for Eliquis is expected to expire around 2028 in the U.S., opening the market to biosimilar competition.
2. How does Eliquis pricing compare to its competitors?
Eliquis’s average wholesale price is comparable to Xarelto but generally higher than warfarin, reflecting differences in clinical profile and patent protection duration.
3. What factors could influence Eliquis’s market share in the next five years?
Regulatory updates, new indications, biosimilar entry, payer negotiations, and emerging clinical evidence are key factors impacting market share.
4. Are there upcoming regulatory approvals that could affect Eliquis?
Potential approval for additional indications or formulations may sustain or expand its market; however, key updates depend on ongoing clinical trials and regulatory submissions.
5. How is reimbursement shaping the actual price paid by patients?
Insurance coverage, tier placement, and co-pay assistance programs influence out-of-pocket costs, often reducing the effective price for many patients.
References
[1] Grand View Research. (2022). Anticoagulants Market Size, Share & Trends.
[2] IQVIA. (2022). US Prescription Data for Anticoagulants.
[3] GoodRx. (2023). Eliquis Pricing and Cost Comparison.
[4] FDA. (2022). Prescription Trends Reports.
